Among the various routes of drug delivery oral route is most preferred route. But conventional dosage form offers few limitations which could be resolved by modifying the existing dosage form. Sustained and controlled drug delivery system helps in maintaince of constant plasma drug concentration and retards the release rate of drug thereby extending the duration of action. There are various formulation strategies for sustained release tablets among which matrix tablet serves as an important tool. Hence the problem like poor patient compliance, multiple dosing, see-saw fluctuations can be easily minimized. Matrix tablets can be formulated by either direct compression or wet granulation method by using a variety of hydrophilic or hydrophobic polymers. The rate of drug release from the matrix is primarily governed by rate and extent of water penetration, swelling of polymer, dissolution and diffusion of drug. Thus, sustained release matrix tablet can offer better patient compliance and could be quite helpful in treatment of chronic diseases. The present article concentrates on oral sustained release tablets with a special emphasis on matrix tablet.
Acyclovir sodium is an antiviral drug used to treat herpes, chicken pox and herpes skin infections. Acyclovir sodium potential as an antiviral drug is limited by its low oral bioavailability (20-30%) with short half-life (2-3 hours) with poor plasma protein binding. There is an opportunity to utilize Acyclovir sodium as an antiviral drug by enhancing the bioavailability by formulation technology. In this paper solid microparticle (o/w) of Acyclovir was prepared by melt dispersion technique. The characterization of drug using scanning electron microscopy, FT-IR, particle size, percentage yield, drug loading capacity, hausner's ratio and carr's index, bulk density and tapped density. In vitro drug release studies using phosphate buffer has shown as formulation F5 sustained release for 17 hrs.
The aim of present is to develop & evaluate Sustained release matrix tablet of Repaglinide. Repaglinide is an effective ant hyperglycemic. But owing to its shorter half life it needs frequent administration In present study, an attempt has been made to develop Sustained release matrix tablet of Repaglinide thereby reducing its frequency of administration & other dose related side effects. Various grades of HPMC (K4M & 15M), sodium alginate & Eudragit L 100 were used as hydrophilic matrix polymer. Croscarmellose was used as swelling agent. Total 12 formulations were prepared in trial batches. The formulations were evaluated for various pre compression & post compression parameters. All the formulations showed compliance with the pharmacopoeial standards. On the basis of evaluated parameters formulation F6 was considered to be the best one. Formulation F6 containing polymer sodium alginate showed 98.67% in-vitro drug release profile. The release data for formulation F6 was fitted to various mathematical models like zero order, first order, Krosmeyer Peppas & Higuchi model. It was observed that drug follows zero order kinetics & Higuchi model.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.